Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Calypso Medical Technologies Inc.

Division of Varian Medical Systems Inc.
www.calypsomedical.com

Latest From Calypso Medical Technologies Inc.

Deals Update

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.

Deals Shaping the Medical Industry (10/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q3 2009

Medical device financing--primarily made up of late venture rounds--totaled just over $1 billion in Q3 2009, a 19% increase over the previous quarter. Acquisition dollars in the industry also surpassed $1 billion and included two $400 million-deals by Abbott. Most of the third quarter financing into in vitro diagnostics and research/analytical came from Qiagen's $628 million FOPO. And Agilent's $1.5 billion purchase of bioanalytical instrument maker Varian was the highest-value takeover.
Medical Device

Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q3 2008

Highlights from the Q3 2008 review of device and diagnostics dealmaking: Led by late-stage rounds, financing for medical device firms--at just over $1bn--showed a slight improvement over the last quarter. IPOs and follow-ons were noticeably absent in Q3, reminiscent of a time in 2003 when the IPO window closed. Not even one of the 13 device M&A transactions reached the billion-dollar mark, but the largest deal, GE Healthcare's buy of Vital Signs for $990mm, came close. In vitro diagnostics/research financings doubled to $643mm led by Illumina's $343mm FOPO. M&A activity in this industry was scant with a mere three transactions. However, Nanogen's reverse merger with Elitech Group--worth $99mm-beat the median M&A deal price ($60mm) over the past five years. Interestingly many in vitro diagnostics players turned to alliances with tech transfer entities in hopes of filling their pipelines.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Monitoring Equipment & Devices
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Varian Medical Systems Inc.
  • Senior Management
  • Edward Vertatschitsch, PhD, Pres. & CEO
    Mark Querry, VP, CFO
    Jed Palmacci, VP, Sales
    J. Nelson Wright, CTO
  • Contact Info
  • Calypso Medical Technologies Inc.
    Phone: (206) 254-0600
    2101 Fourth Ave.
    Ste. 550
    Seattle , WA 98121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register